Jack Stewart discusses SOR-C18 disruption of TRPV6

Jack Stewart, CSO of Soricimed Biopharma explains SOR-C13, a selective inhibitor of TRPV6, binds with affinity and disrupts how TRPV6 functions. Author: Cancer-News Added: 08/23/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts